Close

MIROCALS: Episode MND

Reading Time: 5 minutes A clinical trial of Jedi proportions… The MND Association is backing a new clinical trial in MND, known as MIROCALS. This will be a joint clinical trial between France and the UK that will aim to dampen the overactive immune system by increasing the amount of interleukin-2. It is important to stress that planning for this MND…

Tirasemtiv Phase II clinical trial – results

Reading Time: 4 minutes The top-line results from the Cytokinetics Inc Phase IIb clinical trial of Tirasemtiv were announced last week. Following this announcement, detailed results were then presented on 29 April 2014 at the Annual Academy of Neurology (AAN) meeting. Unfortunately, although the drug was found to be safe, the results concluded that Tirasemtiv did not meet its…

Clinical trials in a dish?

Reading Time: 2 minutes A packed room at the 24th International Symposium on ALS/MND was given a fascinating whistle stop tour covering stem cells, robots and cellular garbage clearing, by Dr Steve Finkbeiner of the University of California, as well as a glimpse into the future of developing ‘disease in a dish’ models of MND. Dr Finkbeiner outlined how…

It’s OK to ask about MND research

Reading Time: 2 minutes The National Institute for Health Research (NIHR) has launched their ‘It’s OK to ask campaign’ which encourages patients and the public to ask about clinical research. The campaign was launched on Monday (20 May 2013), ‘International Clinical Trials Day’ and the NIHR will be promoting this campaign throughout 2013/14. “Clinical research is the way in which…

Adaptive licensing and MND

Reading Time: 3 minutes I have recently updated the clinical trials section of our website with a couple of MND clinical trials that are currently recruiting. This has led me to think about the adaptive licensing discussions that have been taking place recently and how this relates to these MND clinical trials. Adaptive licensing is an idea. An idea that has seen…

Antisense seems to make sense

Reading Time: 3 minutes Results from a phase I clinical trial of a drug known as ISIS 333611 have been published open-access online in the scientific journal Lancet Neurology on 29 March 2013. This is the first time researchers have tested the effects of delivering an antisense oligonucleotide directly into the human cerebral spinal fluid (the fluid between the spinal…